Bormioli Pharma strengthens its presence in the US

In order to support its growth strategy, the leading pharma packaging manufacturer has established a new legal entity in the US, a new commercial branch and a dedicated, on-site team for the North American market. The goal is to be closer to their overseas customers, proposing high added-value solutions and providing a more effective service.

This content was submitted directly to this website by the supplier.

Bormioli Pharma, leading global producer in the pharma packaging market, announced today the strengthening of its presence in the US, establishing a new legal entity – named Bormioli Pharma United States Inc. – in the United States.

This decision is part of the company’s five-year strategic plan and sees the opening of a commercial branch in Philadelphia, hosting an on-site sales team dedicated to the North American market.

Andrea Lodetti, CEO Bormioli Pharma, commented: “Through our internationalization strategy, we aim to be closer to our customers, providing a more effective service for the biggest pharma market in the world. That’s part of our growth strategy plan, aiming to make Bormioli Pharma a truly global player, able to answer to the market challenges with high value-added pharma packaging solutions.”

Acquired in November 2017 by the investment fund Triton, Bormioli Pharma is now a forward-looking independent company showing considerable growth and able to compete on a global scale.

Internationalization is one of the pillars of Bormioli Pharma’s growth strategy, together with the development of a new, outstanding innovation model, and the optimization of the company’s core business.

Bormioli Pharma also plans to strengthen its overseas logistics support through the opening a new warehouse in the United States, scheduled by H1 2019.

More in Home